The burden of disease and the need for a simple staging system in idiopathic pulmonary fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 189, Issue 7, 2014, Pages 765-767

  O'Connell, Oisin J ^a,b   Egan, Jim J ^c,d  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b Department of Medicine National University of Ireland Cork   (Ireland)

^c MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; GAMMA INTERFERON; NINTEDANIB; PIRFENIDONE; PLACEBO;

BURDEN OF DISEASE; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; EDITORIAL; FIBROSING ALVEOLITIS; FOLLOW UP; HEART FAILURE; HUMAN; LUNG CANCER; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MORTALITY; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; SENSITIVITY AND SPECIFICITY; STAGING; SURVIVAL;

CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84897387567     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201402-0306ED     Document Type: Editorial

References (15)

1. Raghu G, Collard HR, Anstrom K.J., Flaherty KR, Fleming TR, King TE Jr, Martinez FJ, Brown KK. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012; 185:1044-1048.
2. Wells AU, Behr J, Costabel U., Cottin V, Poletti V, Richeldi L; European IPF Consensus Group. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. Thorax 2012; 67:938-940.
3. King TE, Albera C, Bradford W.Z., Costabel U., du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW All-cause mortality rate in patients with idiopathic pulmonary fibrosis: implications for the design and execution of clinical trials. Am J Respir Crit Care Med 2014; 189:825-831.
4. Zisman DA, Schwarz M, Anstrom K.J., Collard HR, Flaherty KR, Hunninghake GW; Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; 363:620-628.
5. King TE J.r., Safrin S, Starko K.M., Brown KK, Noble PW, Raghu G, Schwartz DA Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005; 127:171-177.
6. O'Connell O.J., Riddell P, Egan JJ Importance of idiopathic pulmonary fibrosis staging for clinical trial endpoints. Am J Respir Crit Care Med 2013; 187:1271.
7. Blackwell TS, Tager AM, Borok Z, Moore B.B., Schwartz DA, Anstrom KJ, Bar-Joseph Z, Bitterman P, Blackburn M.R., Bradford W., et al. Future directions in idiopathic pulmonary fibrosis research: an NHLBI workshop report. Am J Respir Crit Care Med 2014; 189:214-222.
8. Palevsky PM, Liu KD, Brophy P.D., Chawla LS, Parikh CR, Thakar CV, Tolwani A.J., Waikar SS, Weisbord SD. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis 2013; 61:649-672.
9. Egan JJ, Martinez FJ, Wells A.U., Williams T. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax 2005; 60:270-273.
10. Mogulkoc N, Brutsche MH, Bishop P.W., Greaves SM, Horrocks AW, Egan JJ; Greater Manchester Pulmonary Fibrosis Consortium. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med 2001; 164:103-108.
11. Flaherty KR, Mumford JA, Murray S, Kazerooni E.A., Gross BH, Colby TV, Travis WD, Flint A, Toews G.B., Lynch JP III, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168:543-548.
12. Ley B, Ryerson CJ, Vittinghoff E, Ryu J.H., Tomassetti S., Lee JS, Poletti V, Buccioli M, Elicker B.M., Jones KD, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156:684-691.
13. O'Dwyer D.N., Armstrong ME, Trujillo G, Cooke G., Keane MP, Fallon PG, Simpson AJ, Millar A.B., McGrath EE, Whyte MK, et al. The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2013; 188: 1442-1450.
14. Peljto AL, Zhang Y, Fingerlin T.E., Ma SF, Garcia JG, Richards TJ, Silveira L.J., Lindell KO, Steele MP, Loyd JE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 2013; 309: 2232-2239.
15. O'Connell O.J., Kennedy MP, Henry MT Idiopathic pulmonary fibrosis: treatment update. Adv Ther 2011; 28:986-999.